Equities analysts expect that Immatics (NASDAQ:IMTX) will report $9.62 million in sales for the current quarter, Zacks reports. Two analysts have provided estimates for Immatics’ earnings, with estimates ranging from $8.26 million to $10.97 million. The firm is expected to report its next quarterly earnings results on Tuesday, June 29th.
On average, analysts expect that Immatics will report full year sales of $44.37 million for the current year, with estimates ranging from $37.64 million to $51.80 million. For the next fiscal year, analysts expect that the company will post sales of $40.08 million, with estimates ranging from $38.00 million to $43.78 million. Zacks’ sales averages are a mean average based on a survey of research firms that cover Immatics.
A number of equities research analysts have commented on the company. Zacks Investment Research lowered Immatics from a “hold” rating to a “sell” rating in a research report on Monday, March 22nd. SVB Leerink boosted their price objective on shares of Immatics from $17.00 to $26.00 and gave the company an “outperform” rating in a research report on Tuesday, March 23rd. Finally, Chardan Capital reiterated a “buy” rating on shares of Immatics in a research note on Sunday, April 4th. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. Immatics presently has a consensus rating of “Buy” and a consensus price target of $19.60.
Shares of IMTX stock traded down $0.46 on Thursday, reaching $11.99. 165,621 shares of the company’s stock traded hands, compared to its average volume of 641,543. Immatics has a 12-month low of $8.66 and a 12-month high of $18.42. The business’s 50 day moving average price is $12.32 and its two-hundred day moving average price is $11.08.
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct therapeutic modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.
Featured Story: What does EPS mean?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Immatics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immatics and related companies with MarketBeat.com's FREE daily email newsletter.